Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2009-10-22
2011-10-11
Jiang, Dong (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C424S144100, C530S350000
Reexamination Certificate
active
08034343
ABSTRACT:
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
REFERENCES:
patent: 5488032 (1996-01-01), Dower et al.
patent: 6326472 (2001-12-01), Timans et al.
patent: 6492496 (2002-12-01), Parnet et al.
Arend et al., “Binding of IL-α, I-1L-β, and IL-1 Receptor Antagonist by Soluble IL-1 Receptors and Levels of Soluble IL-1 Receptors in Synovial Fluids,”The Journal of Immunology,153(10):4767-4774, Nov. 15, 1994.
Arend, William P., “Interleukin-1 Receptor Antagonist,” Advances in Immunology, 54:167-227, Jan. 19, 1993.
Auphan et al., “Immunosuppression by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of IkB Synthesis,”Science,270:286-290, Oct. 13, 1995.
Baum et al., “Molecular characterizastion of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34,”The EMBO Journal,13(17):3992-4001, 1994.
Bergers et al, “Alternative promoter usage of the Fos-responsive gene Fit-1 generated mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor,”EMBO Journal,13(5):1176-1188, 1994.
Buckler et al. “Two-step stimulation of B lymphocytes to enter DNA synthesis: synergy between anti-immunoglobulin antibody and cytochalasin on expression of c-myc and a G1-specific gene,” Mol Cell Biol., 8(3):1371-1375 (abstract only), 1988.
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein,” Nature, 344:633-637, Apr. 12, 1990.
Crowell et al., “Functional Bowel Disorders and Dysmenorrhea: Don't Cramp My Style,” Gastroenterology, 109(3):1017-1019, Sep. 1995.
Dinarello, Charles A., “Interleukin-1 and Its Biologically Related Cytokines,” Advances in Immunology, 44:153-205, 1989.
Fauci, Anthony S., :Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy, Science, 262:1011-1014, Nov. 12, 1993.
Greenfeder et al., “Molecular Cloning and Characterization of a Second Subunit of the Interleukin I Receptor Complex,” The Journal of Biological Chemistry, 270(23):13757-13765, 1995.
Hashimoto et al., “TheTollGene ofDrosophila, Required for Dorsal-Ventral Embryonic Polarity, Appears to Encode a Transmembrane Protein,”Cell, 52:269-27, Jan. 29, 1988.
Howard et al., “Soluble tumor necrosis factor receptor: Inhibition of human immunodeficiency virus activation,”Proc. Natl. Acad. Sci. USA, p. 2335, Mar. 1993.
Isselbacher et al., “Eicosanoids and Human Disease,”Harrison's Principles of Internal Medicine, 1(13):433-435, 13th Ed. 1994.
Lord et al., “Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6,” Oncogene, 5(7):1095-1097, Jul. 1990.
Marx, Jean, “How the Glucocorticoids Suppress Immunity,”Science, 270:232-233, Oct. 13, 1995.
Nomura et al., Prediction of the Coding Sequences of Unidentified Human Genes. I. The Coding Sequences of 40 New Genes (KIAA0001-KIAA0040) Deduced by Analysis of Randomly Sampled cDNA Clones from Human Immature Myeloid Cell Line KG-1, DNA Research, 1:27-35, 1994.
Parnet et al., “IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP,” J Biol Chem 271(8):3967-3970, 1996.
Parnet et al., “A Novel Receptor Similar to the Type I Interleukin I Receptor and T1/ST2,” Poster presented at Lake George, NY, Oct. 1995.
Price et al., “Pathophysiology Clinical Concepts of Disease Processes,” p. 36-38, 1986.
Reznikov et al., “IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma,” Proc Natl Acad Sci USA 97(5):2174-2179, 2000.
Rosenberg et al., Immunopathogenesis of HIV Infection, FASEB Journal. 5: p. 2384, Jul. 1991.
Sha et al., “Targeted Disruption of the p50 Subunit of NF-kB Leads to Multifocal Defects in Immune Responses,”Cell, 80:321-330, Jan. 27, 1995.
Sims et al., “Geonomic Organization of the Type I and Type II IL-1 Receptors,” Cytokine, 7(6):483-490, Aug. 1995.
Thanos et al., NF-kB: A Lesson in Family Values, Cell, 80:529-532, Feb. 24, 1995.
Tietz, Norbert W., “7-Lipids, Lipoproteins, and Apolipoproteins,”Textbook of Clinical Chemistryp. 842, 1986.
Torigoe et al., “Purification and characterization of the human interleukin-18 receptor,” J. Biol. Chem. And Mole. Biol., 272(41):25737-24742, 1997.
Weih et al., “Multiorgan Inflammation and Hematopoietic Abnormalities in Mice with a Targeted Disruption of ReIB, a Member of the NF-kB/Rel Family,”Cell, 80:331-340, Jan. 27, 1995.
Yamamoto et al., “Transcriptional Roles of Nuclear Factor kB and Nuclear Factor-Interleukin-6 in the Tumor Necrosis Factor α-Dependent Induction of Cyclooxygenase-2 in MC3T3-E1 Cells,”The Journal of Biological Chemistry, 270(52):31315-31320, 1995.
Parnet Patricia
Sims John E.
Immunex Corporation
Jiang Dong
Wrona Thomas J.
LandOfFree
Methods of treating inflammatory disorders of the lungs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating inflammatory disorders of the lungs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating inflammatory disorders of the lungs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275591